UY28074A1 - Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos - Google Patents
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativosInfo
- Publication number
- UY28074A1 UY28074A1 UY28074A UY28074A UY28074A1 UY 28074 A1 UY28074 A1 UY 28074A1 UY 28074 A UY28074 A UY 28074A UY 28074 A UY28074 A UY 28074A UY 28074 A1 UY28074 A1 UY 28074A1
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- pirazinona
- indolil
- hyperproliferative disorders
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42549002P | 2002-11-12 | 2002-11-12 | |
| US46091503P | 2003-04-07 | 2003-04-07 | |
| US48420203P | 2003-06-30 | 2003-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28074A1 true UY28074A1 (es) | 2004-05-31 |
Family
ID=32314888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28074A UY28074A1 (es) | 2002-11-12 | 2003-11-11 | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1565455A1 (fr) |
| JP (1) | JP2006509840A (fr) |
| KR (1) | KR20050072824A (fr) |
| AR (1) | AR043059A1 (fr) |
| AU (1) | AU2003290744A1 (fr) |
| BR (1) | BR0316169A (fr) |
| CA (1) | CA2505819A1 (fr) |
| EC (1) | ECSP055851A (fr) |
| HR (1) | HRP20050496A2 (fr) |
| MA (1) | MA27557A1 (fr) |
| MX (1) | MXPA05004779A (fr) |
| NO (1) | NO20052796L (fr) |
| PE (1) | PE20040832A1 (fr) |
| PL (1) | PL376867A1 (fr) |
| TW (1) | TW200418834A (fr) |
| UY (1) | UY28074A1 (fr) |
| WO (1) | WO2004043950A1 (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| WO2005049593A2 (fr) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | Promoteurs de l'apoptose contenant n-acylsulfonamide |
| CA2546300C (fr) | 2003-11-20 | 2012-10-02 | Janssen Pharmaceutica N.V. | 2-quinolinones et 2-quinoxalinones substituees par 6-alcenyle et 6-phenylalkyle utilisees comme inhibiteurs de la poly(adp-ribose) polymerase (parp) |
| CA2546002C (fr) | 2003-11-20 | 2012-09-18 | Janssen Pharmaceutica N.V. | 2-quinolinones et 2 quinoxalinones a substitution 7-phenylalkyl tenant lieu d'inhibiteurs de poly(adp-ribose) polymerase inhibitors |
| US20070105851A1 (en) * | 2003-11-21 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| CN1980913B (zh) | 2004-06-30 | 2011-12-14 | 詹森药业有限公司 | 作为parp抑制剂的喹唑啉二酮衍生物 |
| ES2563954T3 (es) | 2004-06-30 | 2016-03-16 | Janssen Pharmaceutica Nv | Derivados de ftalazina como inhibidores de PARP |
| MXPA06014543A (es) | 2004-06-30 | 2007-03-23 | Janssen Pharmaceutica Nv | Derivados de quinazolinona como inhibidores de la poli(adp-ribosa)polimerasa-i. |
| PL1819698T3 (pl) | 2004-11-17 | 2011-08-31 | Rexahn Pharmaceuticals Inc | Pochodne 1-[(6-podstawione alkoksychinoksalinylo)aminokarbonylo]-4-(hetero)arylopiperazyny |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| PT1888550E (pt) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| WO2008107478A1 (fr) | 2007-03-08 | 2008-09-12 | Janssen Pharmaceutica Nv | Dérivés de quinolinone comme inhibiteurs de parp et de tank |
| WO2009118382A1 (fr) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Tétrahydrophénanthridinones et tétrahydrocyclopentaquinolinones comme inhibiteurs de la polymérisation de la tubuline et de parp |
| WO2010053757A1 (fr) * | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | Inhibiteurs, à base de 2-oxoquinoxaline, des canaux sodiques tardifs |
| US20100113514A1 (en) | 2008-10-30 | 2010-05-06 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
| EP2352725A1 (fr) * | 2008-11-07 | 2011-08-10 | Wyeth LLC | Modulateurs de lxr à base de quinoxaline |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| PL3122358T3 (pl) | 2014-03-26 | 2021-06-14 | Astex Therapeutics Ltd. | Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| RU2715893C2 (ru) | 2014-03-26 | 2020-03-04 | Астекс Терапьютикс Лтд | Комбинации ингибитора fgfr и ингибитора igf1r |
| EA201692091A1 (ru) * | 2014-04-18 | 2017-04-28 | Милленниум Фармасьютикалз, Инк. | Хиноксалиновые соединения и их применение |
| EP3247705B1 (fr) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Composés quinazoline et quinoléine, et utilisations de ceux-ci en tant qu'inhibiteurs nampt |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
| HUE057090T2 (hu) | 2015-09-23 | 2022-04-28 | Janssen Pharmaceutica Nv | BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében |
| TW202317086A (zh) * | 2021-09-29 | 2023-05-01 | 加拿大商修復治療公司 | 化合物、醫藥組成物及製備化合物之方法及其使用方法 |
| WO2024069592A1 (fr) * | 2022-09-29 | 2024-04-04 | Repare Therapeutics Inc. | Composés de n-([(l, 3,4-thiadiazolyle) substitué en position 5 ou (l,3-thiazolyl)](substitué)carboxamide, compositions pharmaceutiques et procédés de préparation de composés amides et leur utilisation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
-
2003
- 2003-11-05 AR ARP030104059A patent/AR043059A1/es unknown
- 2003-11-10 WO PCT/US2003/036003 patent/WO2004043950A1/fr active Application Filing
- 2003-11-10 KR KR1020057008396A patent/KR20050072824A/ko not_active Application Discontinuation
- 2003-11-10 JP JP2005507146A patent/JP2006509840A/ja active Pending
- 2003-11-10 MX MXPA05004779A patent/MXPA05004779A/es not_active Application Discontinuation
- 2003-11-10 EP EP03783328A patent/EP1565455A1/fr not_active Withdrawn
- 2003-11-10 BR BR0316169-2A patent/BR0316169A/pt not_active Application Discontinuation
- 2003-11-10 AU AU2003290744A patent/AU2003290744A1/en not_active Abandoned
- 2003-11-10 CA CA002505819A patent/CA2505819A1/fr not_active Abandoned
- 2003-11-10 PL PL376867A patent/PL376867A1/pl unknown
- 2003-11-11 UY UY28074A patent/UY28074A1/es not_active Application Discontinuation
- 2003-11-11 TW TW092131443A patent/TW200418834A/zh unknown
- 2003-11-11 PE PE2003001136A patent/PE20040832A1/es not_active Application Discontinuation
-
2005
- 2005-06-02 HR HR20050496A patent/HRP20050496A2/hr not_active Application Discontinuation
- 2005-06-09 NO NO20052796A patent/NO20052796L/no not_active Application Discontinuation
- 2005-06-09 MA MA28322A patent/MA27557A1/fr unknown
- 2005-06-10 EC EC2005005851A patent/ECSP055851A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20050496A2 (en) | 2006-06-30 |
| WO2004043950A1 (fr) | 2004-05-27 |
| ECSP055851A (es) | 2005-09-20 |
| MXPA05004779A (es) | 2005-07-22 |
| NO20052796D0 (no) | 2005-06-09 |
| PL376867A1 (pl) | 2006-01-09 |
| EP1565455A1 (fr) | 2005-08-24 |
| KR20050072824A (ko) | 2005-07-12 |
| AR043059A1 (es) | 2005-07-13 |
| MA27557A1 (fr) | 2005-10-03 |
| TW200418834A (en) | 2004-10-01 |
| JP2006509840A (ja) | 2006-03-23 |
| NO20052796L (no) | 2005-06-09 |
| CA2505819A1 (fr) | 2004-05-27 |
| AU2003290744A1 (en) | 2004-06-03 |
| PE20040832A1 (es) | 2005-01-27 |
| BR0316169A (pt) | 2005-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28074A1 (es) | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos | |
| ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
| EA200501333A1 (ru) | 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ | |
| WO2007020103A3 (fr) | Nouvelle utilisation de composes peptidiques pour traiter une douleur musculaire | |
| PA8565901A1 (es) | Derivados de dihidrobenzodiazepin-2-ona iii | |
| ECSP085481A (es) | Profármacos de aminoácidos excitadores | |
| ECSP045274A (es) | N-aminoacetil-pirrolidina-2-carbonitrilosy su uso como inhibidores ddp-iv | |
| UY28014A1 (es) | Compuestos quimicos | |
| BRPI0412404A (pt) | uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea | |
| MY135233A (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials | |
| DOP2002000447A (es) | 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5 onas como inhibidores de fosfodiesterasas | |
| IS7872A (is) | Pýrrólópýrimidín afleiður | |
| CY1109722T1 (el) | Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole | |
| ECSP077130A (es) | Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos | |
| UY29170A1 (es) | Adeninas sustituidas y usos de las mismas | |
| CY1109992T1 (el) | Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα | |
| HN2003000080A (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
| UY27203A1 (es) | Bencimidazoles útiles en el tratamiento de la disfunción sexual | |
| ECSP056174A (es) | Acidos hidroxamicos utiles en el tratamiento detrastornos hiperproliferativos | |
| SV2006002238A (es) | Inhibidores de la adenilato ciclasa soluble ref. p-sv-78. 959/gh | |
| ATE371662T1 (de) | Siliziumverbindungen und deren verwendung | |
| TW200745053A (en) | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | |
| DOP2003000749A (es) | Derivados de indolil pirazinona utile para el tratamiento de trastornos hiperproliferativos | |
| IS8034A (is) | Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla | |
| DE60304360D1 (de) | N-aryl-2-oxazolidinone und deren derivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20160120 |